

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

11 Jul 2026

### The effect of selenium and vit E supplementation on anti-mullerian hormone (AMH) index and antral follicle count in infertile women with occult premature ovarian insufficiency: A randomized controlled clinical trial

#### Protocol summary

##### Study aim

- Comparison of AMH concentration 12 months after initiation of intervention in the group receiving selenium and vitamin E and placebo group with control of the effect of AMH concentration before intervention
- Comparison of the number of ovarian antral follicles 12 months after intervention in the group receiving selenium and vitamin E and placebo group with control of the effect of number of antral ovarian follicles before intervention
- Comparison of ovarian volume 12 months after intervention in the group receiving selenium and vitamin E and placebo group with control of ovarian volume before intervention
- Determining the frequency of adverse events in the treatment group for selenium and vitamin E recipients and the placebo group

##### Design

This is a randomized, controlled triple blinded with two arm parallel group clinical trial that have been designed for Occult POI patients referred to Al-Zahra clinic and clinics and clinics affiliated to Tabriz University of Medical Sciences. . The sample size is 35 in each group

##### Settings and conduct

This is a randomized, controlled triple blinded with two arm parallel group clinical trial that have been designed for Occult POI patients referred to Al-Zahra clinic and clinics and clinics affiliated to Tabriz University of Medical Sciences. In this study, the participants and the person who performed the statistical analysis will be blinded

##### Participants/Inclusion and exclusion criteria

Entry Criteria: Accepting informed written consent  
Women aged 20 to 40 years old Menstrual cycle Having two ovaries There is no evidence of endocrine disorders (diabetes, thyroid disorders, Addison's disease, etc.) by asking the patient and checking out the results of previous patient tests. Occult POI (hormone AMH <1 ng / ml, reduced ovarian reserve, less than 5 antral follicles,

reduced ovarian volume to less than 2.5 cubic centimeters, or all three cases) With BMI <30, the weight and height in this study will be measured by the researcher and the BMI will be calculated according to the formula below.  $BMI = (WEIGHT (kg)) / (LENGTH (m)^2)$  Non-arrival criteria: Drug Addiction and Tobacco Use Tend to use donation eggs Having evidence of OVERT POI (FSH > 15 or amenorrhea for more than 3 months) Supplementation of Selenium and Vitamin E three months before the onset of intervention Having a history of radiotherapy and chemotherapy Taking anticoagulants (co-administration of vitamin E with these drugs increases the risk of bleeding).

##### Intervention groups

The intervention group will receive Selenium pills and vitamin E for three months. The other group will receive the placebo of these two supplements. Because both (selenium and vitamin E) are the cofactor of the enzyme GPX, there is therefore no need for a separate group to check vitamin E or selenium alone

##### Main outcome variables

AMH concentration 12 months after intervention: Number of antral follicles in ovarian 12 months after the intervention: Volume of ovaries 12 months after intervention: The incidence of side effects of selenium and vitamin E

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20160410027311N6**

Registration date: **2018-04-30, 1397/02/10**

Registration timing: **prospective**

Last update: **2018-04-30, 1397/02/10**

Update count: **0**

**Registration date**  
2018-04-30, 1397/02/10

**Registrant information**

**Name**  
Behnaz Sadeghzadeh Oskouei

**Name of organization / entity**  
Tabriz University of Medical Sciences

**Country**  
Iran (Islamic Republic of)

**Phone**  
+98 41 3479 0364

**Email address**  
sadeghzadehb@tbzmed.ac.ir

**Recruitment status**  
**Recruitment complete**

**Funding source**

**Expected recruitment start date**  
2018-05-04, 1397/02/14

**Expected recruitment end date**  
2018-09-05, 1397/06/14

**Actual recruitment start date**  
empty

**Actual recruitment end date**  
empty

**Trial completion date**  
empty

**Scientific title**  
The effect of selenium and vit E supplementation on anti-mullerian hormone (AMH) index and antral follicle count in infertile women with occult premature ovarian insufficiency: A randomized controlled clinical trial

**Public title**  
The effect of selenium and vit E supplementation on Oogenesis improvement in infertile women with occult premature ovarian insufficiency: A randomized controlled clinical trial

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**  
Accepting informed written consent Women aged 20 to 40 years old Menstrual cycle Having two ovaries There is no evidence of endocrine disorders (diabetes, thyroid disorders, Addison's disease, etc.) by asking the patient and checking out the results of previous patient tests. Occult POI (hormone AMH <1 ng / ml, reduced ovarian reserve, less than 5 antral follicles, reduced ovarian volume to less than 2.5 cubic centimeters, or all three cases) With BMI <30, the weight and height in this study will be measured by the researcher and the BMI will be calculated according to the formula below. BMI = (WEIGHT (kg)) / (LENGTH (m ^ 2))

**Exclusion criteria:**  
Drug Addiction and Smoking The tendency to use donated eggs Having evidence of OVERT POI (FSH> 15 or amenorrhea for more than 3 months)  
Supplementation of selenium and vitamin E three

months before the onset of intervention Having a history of radiotherapy and chemotherapy The use of anticoagulants (co-administration of vitamin E with these drugs increases the risk of bleeding)

**Age**  
From **20 years** old to **40 years** old

**Gender**  
Female

**Phase**  
N/A

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**  
Target sample size: **70**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
Participants will be randomly assigned 1 to 1 using the 4 and 6 block method right before the intervention begins.

**Blinding (investigator's opinion)**  
Triple blinded

**Blinding description**  
Blinding the allocation by a non-trafficker is done in the sampling and the received intervention (drug or placebo) is placed in the numbered blank opaque glasses, thus identifying the placement of the individuals. Glasses will be numbered from 1 to 70. The first person will be given the number one glass, and this will continue until the end of the sampling.

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

**Ethics committee**

**Name of ethics committee**  
Ethics Committee of Tabriz University of Medical Sciences

**Street address**  
Azadi St., Golghast St., Tabriz University of Medical Sciences, Central Building No. 2, Third Floor, Research Deputy Directorate

**City**  
Tabriz

**Province**  
East Azarbaijan

**Postal code**

5166614766

**Approval date**

2018-03-12, 1396/12/21

**Ethics committee reference number**

IR.TBZMED.REC.1396.1255

**Health conditions studied****1****Description of health condition studied**

occult premature ovarian insufficiency

**ICD-10 code**

E28.3

**ICD-10 code description**

Primary ovarian failure

**Primary outcomes****1****Description**

Concentration of anti-mullerian hormone (AMH)

**Timepoint**

Before the intervention begins and 12 months after the intervention begins

**Method of measurement**

To monitor the level of anti-mullerian hormone, blood sampling will be performed on the day of referral from the Brachial vein and will be immediately transferred to the laboratory and will be used with an ELISA kit.

**2****Description**

Number of ovarian antral follicles

**Timepoint**

Before the intervention begins and 12 months after the intervention begins

**Method of measurement**

Transvaginal ultrasonography of the ovary on the third day of the menstrual cycle, performed by a radiologist and a device for all participants to check the number of antral follicles.

**Secondary outcomes****1****Description**

Ovarian volume

**Timepoint**

Before the intervention begins and 12 months after the intervention begins

**Method of measurement**Ovarian volume with the same ultrasound on the third day of menstruation using the following formula Ovarian volume = Length × height × width ×  $\pi$  / 6 It will be calculated for each ovary separately**2****Description**

The incidence of side effects of selenium and vitamin E and their placebo

**Timepoint**

After the end of the intervention

**Method of measurement**

The side effects of medicines will be questioned according to the checklist given during supplements or placebo and will be recorded in the checklist.

**Intervention groups****1****Description**

Intervention group: The intervention group will receive one tablet of selenium 200 micrograms daily and one vitamin E 400 units per day for 90 days.

**Category**

Treatment - Drugs

**2****Description**

Control group: The control group will receive the placebo of Selenium and vitamin E for 90 days.

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Infertility Clinic of Al-Zahra Hospital

**Full name of responsible person**

Safiyeh Farhadi Dizaji

**Street address**

Alzahra Hospital , Artesh Street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138663134

**Phone**

+98 41 3553 9161

**Fax**

+98 41 3556 6449

**Email**

alzahrahospital@tbzmed.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr Mohammadreza Rashidi

**Street address**

Tabriz University of Medical Sciences, Golghasht St.,  
Azadi St., Central Building No. 2, Third Floor,  
Department of Research Vice-Chancellery of Tabriz  
University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3336 4658

**Email**

Medical.librarian@chmail.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Safiyeh Farhadi Dizaji

**Position**

Midwifery Masters student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Midwifery

**Street address**

Midwifery Department, Nursing and Midwifery  
Faculty, South Shariati Street, Tabriz, Iran

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138947977

**Phone**

+98 41 3479 6770

**Fax****Email**

s63farhadi@gmail.com

**Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Behnaz Sadeghzadeh Oskouei

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Reproductive Biology

**Street address**

Faculty of Nursing & Midwifery, South Shariati Street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138947977

**Phone**

+98 41 3479 0364

**Fax**

+98 41 3479 6969

**Email**

sadeghzadehb@tbzmed.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Safiyeh Farhadi Dizaji

**Position**

Midwifery masters student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Midwifery

**Street address**

South Shariati St. - Faculty of Nursing and Midwifery

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138947977

**Phone**

+98 41 3479 6770

**Email**

s63farhadi@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no program for publishing participant data file

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

The results of the clinical study will be published as a article

**When the data will become available and for how long**

Immediately after publishing the results

**To whom data/document is available**

All researchers

**Under which criteria data/document could be used**

Scientific citation based on article

**From where data/document is obtainable**

email: sadeghzadehb@tbzmed.ac.ir

**What processes are involved for a request to access data/document**

Up to one week after communication by email

**Comments**